Clinical Trials
Phase III Study Of Viaskin Peanut – Allergic Of Patients One To Three Years Of Age Initiated By DBV Technologies
 DBV Technologies announced that the first patient has been enrolled in EPITOPE ( EPIT in TO ddlers with PE anut Allergy), a global, Phase III clinical trial assessing the safety and efficacy of Viaskin Peanut for the treatment...
Clinical Trials
Positive Results From The Phase 2 AESOP Trial Evaluating OCA For The Treatment Of Patients With Primary Sclerosing Cholangitis Announced By Intercept
 Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Phase 2 AESOP trial evaluating obeticholic acid (OCA) for...
Clinical Trials
Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017
Clinical and laboratory personnel with the need to store vaccines, pharmaceuticals and other molecular or biological samples safely can benefit from a new series of lab-grade undercounter refrigerators that are designed to minimize energy usage and noise, while maintaining...
Clinical Trials
Spheryx Awarded Phase II NIH SBIR Grant to Support Extension of Total Holographic Characterization
Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for $1,500,000 over 2 years to support the modification of their proprietary Total Holographic Characterization®...
Clinical Trials
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Viking Therapeutics, Inc , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK5211 in patients who...
Clinical Trials
Cannabics Pharmaceuticals Receives Positive Results In Drug Sensitivity Tests On CTCs
Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. These results greatly strengthen the company's previously accumulated data...
Clinical Trials
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Boston Biomedical Inc, Â announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ (gastroesophageal junction) cancer will be unblinded. This decision is based on...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
